Frequency and spectrum of mitochondrial 12S rRNA variants in 440 Han Chinese hearing impaired pediatric subjects from two otology clinics

Department of Otolaryngology, Ningbo Medical Center, Li Huili Hospital, Ningbo, Zhejiang, China.
Journal of Translational Medicine (Impact Factor: 3.93). 01/2011; 9(1):4. DOI: 10.1186/1479-5876-9-4
Source: PubMed


Aminoglycoside ototoxicity is one of the common health problems. Mitochondrial 12S rRNA mutations are one of the important causes of aminoglycoside ototoxicity. However, the incidences of 12S rRNA mutations associated with aminoglycoside ototoxicity are less known.
A total of 440 Chinese pediatric hearing-impaired subjects were recruited from two otology clinics in the Ningbo and Wenzhou cities of Zhejiang Province, China. These subjects underwent clinical, genetic evaluation and molecular analysis of mitochondrial 12S rRNA. Resultant mtDNA variants were evaluated by structural and phylogenetic analysis.
The study samples consisted of 227 males and 213 females. The age of all participants ranged from 1 years old to 18 years, with the median age of 9 years. Ninety-eight subjects (58 males and 40 females) had a history of exposure to aminoglycosides, accounting for 22.3% cases of hearing loss in this cohort. Molecular analysis of 12S rRNA gene identified 41 (39 known and 2 novel) variants. The incidences of the known deafness-associated 1555A > G, 1494C > T and 1095T > C mutations were 7.5%, 0.45% and 0.91% in this entire hearing-impaired subjects, respectively, and 21.4%, 2% and 2% among 98 subjects with aminoglycoside ototoxicity, respectively. The structural and phylogenetic evaluations showed that a novel 747A > G variant and known 839A > G, 1027A > G, 1310C > T and 1413T > C variants conferred increased sensitivity to aminoglycosides or nonsyndromic deafness as they were absent in 449 Chinese controls and localized at highly conserved nucleotides of this rRNA. However, other variants were polymorphisms. Of 44 subjects carrying one of definite or putative deafness-related 12S rRNA variants, only one subject carrying the 1413T > C variant harbored the 235DelC/299DelAT mutations in the GJB2 gene, while none of mutations in GJB2 gene was detected in other 43 subjects.
Mutations in mitochondrial 12S rRNA accounted for ~30% cases of aminoglycoside-induced deafness in this cohort. Our data strongly support the idea that the mitochondrial 12S rRNA is the hot spot for mutations associated with aminoglycoside ototoxicity. These data have been providing valuable information and technology to predict which individuals are at risk for ototoxicity, to improve the safety of aminoglycoside antibiotic therapy, and eventually to decrease the incidence of deafness.

Download full-text


Available from: Jianxin Lu
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: 35delG mutation in the GJB2 (gap junction protein beta 2, connexin 26) gene is the most frequent mutation in patients with non-syndromic autosomal recessive deafness. The A1555G mutation in the mitochondrial 12S rRNA is another important genetic alteration, and is associated with aminoglycoside-induced deafness. The aim of this study was to explore the etiology of deafness and the prevalence of both mutations in the study cases. Materials and Methods: We examined audiological and dysmorphological features of all children at the Gelibolu School for the deaf. A questionnaire investigating prenatal, perinatal and postnatal etiological causes of deafness was prepared, and pedigree analysis was performed for each individual. After ENT examination, audiological tests and mutation analysis with the RT PCR method were carried out. Results: The GJB2 35delG and mitochondrial A1555G mutations were detected in 12% and 10% of all deaf school children, respectively. The percentages of genetic, acquired, both genetic and environmental, and unknown etiologies were 62.5, 20.3, 15.6 and 1.6, respectively. One patient had both Waardenburg Syndrome and the mitochondrial A1555G mutation, and one patient carried both 35delG and mitochondrial A1555G mutations. Interestingly, one sporadic case, who developed deafness after fever and aminoglycoside treatment, was found to have a homozygous 35delG mutation. His parents and healthy brother were heterozygous for the mutation. Discussion: Our results showed that dysmorphologic examination and mutation analysis are important for the clarification of etiology, and that they can be helpful for genetic counselling.
    Full-text · Article · Jan 2011 · Journal of International Advanced Otology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Drug-induced mitochondrial toxicity is rapidly gaining recognition within the pharmaceutical industry as a contributor to compound attrition and post-market drug withdrawals. This article describes the mechanisms which lead to drug-induced mitochondrial toxicity, discusses high-throughput in vitro assays which are currently being used to identify mitochondrial dysfunction, and provides an overview on some of the drugs which impair mitochondrial function. While considerable progress has been made in the development of high-throughput assays to screen for mitochondrial impairment in vitro, much remains to be done. This includes the development of in silico models to predict drug-induced mitochondrial impairment, wider acceptance of suitable animal models, identification and validation of relevant biomarkers, and the translation of in vitro/in vivo results to clinical outcomes.
    No preview · Article · Jun 2011 · Current pharmaceutical design
  • [Show abstract] [Hide abstract]
    ABSTRACT: An integrated vestibular-cochlear implant can be rapidly prototyped and clinically tested by modifying an existing modern cochlear implant. The modifications include addition of gyroscope sensors and reallocation of several electrodes that are normally used for auditory nerve stimulation to the semicircular canals, while sharing the external DSP processor and the internal receiver/stimulator. This paper discusses the validation issues related to hardware and software design that arise in integrating electric hearing and balance onto a single device. The device's initially targeted population will be deaf individuals who also have vestibular impairment since there is a strong ethical justification for vestibular implantation along with minimal additional surgical risk. Because of widespread usage of ototoxic drugs and unique genetic mutations, the patient population with both impaired hearing and balance function is especially prevalent in Asian countries such as China and India. Should such an integrated vestibular-cochlear implant be verified, it could be used to restore balance or treat a wide array of vestibular disorders.
    No preview · Article · Aug 2011 · Conference proceedings: ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference
Show more